Understanding the endocannabinoid system in cats and dogs

Gaining a deeper understanding of the role and function of the endocannabinoid system in dogs and cats can aid you in talking to your clients about CBD and hemp.

The Endocannabinoid System (ECS) is a major lipid signaling system comprising of endogenous cannabinoids, their receptors, and metabolic enzymes that play a critical homeostatic role in processing and modulating various bodily functions in dogs and cats1-3. This ubiquitous system mediates a homeostatic balance of the nervous and immune systems in conjunction with other organ systems3. Research suggests that a balanced ECS promotes appetite, sleep, mood regulation and stability, gait, pain perception, memory, body temperature, immunity, reproduction and fertility in both humans and pets.  When ECS is out of balance due to lack of enough endocannabinoids, many negative physical signs are often observed in dogs, including digestive issues (vomiting, irregular bowels, diarrhea), poor appetite, sleep issues, stress, anxiety/fear and aggression, lethargy and lack of activity, poor balance and coordination, pain and inflammation. Targeting the ECS with Phytocannabinoids has been shown to trigger the same physiological effects similar to endocannabinoids, thereby promoting systemic well-being1.

A look at the terminology

Cannabinoids, endocannabinoids and phytocannabinoids

The three kinds of cannabinoids that bind to the cannabinoid receptors, which activate the ECS, include endocannabinoids, synthetic cannabinoids, and phytocannabinoids4.

There are two endocannabinoids; anandamide (AEA) and 2-arachidonoylglyerol (2-AG) that are produced from lipids (fats) in the body5. These endocannabinoids are similar but also have a specific role within the Central Nervous System (CNS), including neuromodulator, neuroprotection, modulating anxiety, memory, and learning1.

Endocannabinoids also have functions beyond the CNS, including the immune system; they interact with the cannabinoid receptors6. Phytocannabinoids are plant-based chemicals found in cannabis with limited amounts found in other plants and herbs7. Synthetic cannabinoids were developed to interact with the specifications with the ECS8.

Cannabinoid receptors

There are two key cannabinoid receptors – cannabinoid receptor 1 (CB1) and cannabinoid receptor 2 (CB2) – located throughout the body1. CB1 is known to be psychoactive, neuromodulatory, and a pain receptor found in the brain, fat, liver, skeletal, and muscular tissues9. CB2 is responsible for the anti-inflammatory functions located in cells that are responsible for immune function and may also be found in the CNS. CB2 also plays a strong role in immune function10. CB1 is also expressed on immune cells, so they’re both important but delineated in specific roles.

The role of enzymes

After endocannabinoids finalize their functions, they need to be broken down in the body. This is done by two main enzymes11:

  • fatty acid amide hydrolase (FAAH) that breaks down AEA
  • monoacylglycerol acid lipase (MGL) that normally breaks down 2-AG

Animal versus human

The animal and human endocannabinoid systems are similar with respect to the cellular processes and organ systems. The major difference is the distribution of the CB1 receptors in dogs compared to humans. Studies have shown the higher number of CB1 receptors in the hind brain structures (cerebellum, brain stem, and medulla oblongata) of canine species when compared to humans12. THC has a greater affinity for CB1 receptors. Hence, exerting a unique neurological action “static ataxia” when stimulated by THC due to high concentration of CB1 receptors in the cerebellum of canine species1. The CB1 and CB2 receptors are structurally somewhat similar, except for their respective anatomical distribution in the central nervous system and immune system1. A great deal of data exists on the role of phytocannabinoids in promoting balance of ECS by differential activation of CB1 and CB2 receptors present throughout the body system when administered1,3,13.

Full and broad-spectrum hemp oil products containing less than 0.3% THC are very beneficial in this case. Therefore, recommended dosage of hemp oil supplementation (based on body weight of feline and canine candidates) needs to be followed.

Backed by science

There is considerable evidence regarding clinical and health benefits from phytocannabinoids in humans. However, there is still little information and lack of sufficient evidence-based studies regarding the same benefits in animals, except for studies performed in experimental laboratory animals. Scientific research evidence clearly shows that ECS is intimately involved in the regulation of most physiological processes in animal systems1. A balanced ECS tone (the proper functioning of ECS) plays an important role in regulating the neurological, endocrine, musculoskeletal and immune systems through a complex cellular network to ameliorate pain and inflammation, modulate metabolism, support bone health, and promote digestive health1, 3, 5, 7, 8, 11.

Recommending hemp to your patients

ECS plays a direct role in physiological homeostasis, as it regulates nearly every metabolic process in an animal’s body. As backed by science, a well-balanced ECS will encourage favorable conditions in the animal’s body, impacting their ability to self-manage metabolic stress, anxiety, depression, pain, inflammation and support overall health and systemic well-being. When we understand how full and broad spectrum hemp oil interacts with their ECS, we can potentially provide relief from certain health ailments and improve their quality of life.


1Silver RJ. The Endocannabinoid System of Animals. Animals (Basel). 2019;9(9):686. Published 2019 Sep 16. doi:10.3390/ani9090686

2Ritter S, Zadik-Weiss L, Almogi-Hazan O, Or R. Cannabis, One Health, and Veterinary Medicine: Cannabinoids’ Role in Public Health, Food Safety, and Translational Medicine. Rambam Maimonides Med J. 2020 Jan 30;11(1):e0006. doi: 10.5041/RMMJ.10388. PMID: 32017686; PMCID: PMC7000163.

3Freundt-Revilla J, Heinrich F, Zoerner A, Gesell F, Beyerbach M, et al. (2018) The endocannabinoid system in canine Steroid-Responsive Meningitis-Arteritis and Intraspinal Spirocercosis. PLOS ONE 13(2): e0187197. https://doi.org/10.1371/journal.pone.0187197

4Cabral, G. A., Rogers, T. J. & Lichtman, A. H. Turning Over a New Leaf: Cannabinoid and Endocannabinoid Modulation of Immune Function. J Neuroimmune Pharmacol 10, 193-203, doi:10.1007/s11481-015-9615-z (2015).

5Kaur, R., Ambwani, S. R. & Singh, S. Endocannabinoid System: A Multi-Facet Therapeutic Target. Curr Clin Pharmacol 11, 110-117 (2016).

6Sulcova, E.; Mechoulam, R.; Fride, E. Biphasic Effects of Anandamide. Pharmacol. Biochem. Behav. 1998, 59, 347–352.

7Munro, S., Thomas, K. L. & Abu-Shaar, M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 365, 61-65, doi:10.1038/365061a0 (1993)

8Russo, E. B. Beyond Cannabis: Plants and the Endocannabinoid System. Trends in pharmacological sciences 37, 594-605, doi:10.1016/j.tips.2016.04.005 (2016).

9Pertwee, R.G. Cannabinoid receptors and pain. Prog. Neurobiol. 63, 569–611 (2001)

10Turcotte C, Blanchet MR, Laviolette M, and Flamand N. The CB2 receptor and its role as a regulator of inflammation. Cell Mol Life Sci. 73(23): 4449-4470 (2016). doi: 10.1007/s00018-016-2300-4

11Cable JC, Tan GD, Alexander SPH, and O’Sullivan SE. The effects of obesity, diabetes and metabolic syndrome on the hydrolytic enzymes of the endocannabinoid system in animal and human adipocytes. Lipids in Health and Disease, 13; 43 (2014)

12Herkenham, M.; Lynn, A.B.; Little, M.D.; Johnson, M.R.; Melvin, L.S.; de Costa, B.R.; Rice, K.C. Cannabinoid receptor localization in brain. Proc. Natl. Acad. Sci. USA, 87, 1932–1936 (1930).

13Paula Morales, Dow P. Hurst, and Patricia H. Reggio. Prog Chem Org Nat Prod.103: 103–131 (2017). doi: 10.1007/978-3-319-45541-9_4

IVCVX Bottom Banner
Previous articleUnderstanding the role of homeopathy in epidemics
Next articleStarting a career in veterinary medicine
Dr. Saradhadevi Varadharaj has more than 18 years of experience in strategic life sciences research. She received her BS, MS, M. Phil, and Ph.D in Medical Biochemistry studying molecular and cellular signaling. She was awarded Senior Research Fellowship by Council of Scientific and Industrial Research for her graduate work on “Characterization of red blood cell anion exchange protein in Renal Failure patients”. She continued her post-doctoral research in Paris, upon receiving a fellowship from INSERM and later at The Ohio State University, investigating gene expression mechanisms involved in the treatment of Spinal Muscular Atrophy and cardiovascular dysfunction. Her passion and expertise in cardiovascular health motivated her independent research. Saradha joined the team at Standard Process Inc. in February 2018 and serves as the Director of Clinical Science.
Jody has been providing clinical support for veterinarians, technicians and staff members at Standard Process for over 12 years. She is passionate about the importance of nutrition and enjoys educating veterinary professionals on the benefits that whole food-based supplements can provide to their patients. She earned her veterinary technician certification after receiving her associate's degree from Madison Area Technical College, in Madison, Wisconsin and worked in a mixed animal practice for 11 years prior to joining the Standard Process team. When not at work, Jody loves spending time with her husband, their 7 children, their chocolate Lab Kona and their black Lab Echo.


Please enter your comment!
Please enter your name here